Comparing Semaglutide, Tirzepatide, Mounjaro, Zepbound & GLP-1s

GLP-1 Receptor Agonists: A New Frontier in Weight Loss

GLP-1 (Glucagon-Like Peptide-1) receptor agonists mimic a hormone that helps regulate:

• Blood sugar

• Appetite

• Digestion

By enhancing satiety and slowing gastric emptying, GLP-1s reduce calorie intake and support weight loss.

Semaglutide (Ozempic, Wegovy)

• Brand names: Ozempic (for diabetes), Wegovy (for weight loss)

• Mechanism: GLP-1 receptor agonist

• Dosing: Weekly injection

• FDA approval:

  • Ozempic: Type 2 diabetes

  • Wegovy: Chronic weight management (2021)

• Average weight loss: ~15% of body weight (with lifestyle changes)

• Side effects:

  • Nausea, vomiting, constipation

  • Rare risk of pancreatitis, gallstones

• Cost: ~$1,000+/month without insurance

Best for: Individuals with obesity (BMI ≥30 or ≥27 with comorbidities) who do not respond to diet and exercise alone.

Tirzepatide (Mounjaro, Zepbound)

• Brand names:

  • Mounjaro: FDA-approved for type 2 diabetes (2022)

  • Zepbound: Approved for obesity (Nov 2023)

• Mechanism: Dual agonist of GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide)

• Dosing: Weekly injection

• Efficacy: More weight loss than semaglutide

  • Average: Up to 22.5% of body weight in trials (Zepbound)

• Side effects:

  • Similar to semaglutide, with potential for greater GI effects

• Cost: Similar to or slightly more than semaglutide

Best for: Patients needing more aggressive weight loss; may outperform semaglutide in certain populations.

Mounjaro vs. Zepbound

Though both contain tirzepatide, their FDA-approved uses differ:

• Mounjaro: Type 2 diabetes

• Zepbound: Obesity/weight management

Insurance coverage often hinges on these distinctions. Zepbound has a dedicated approval for weight loss, enabling better coverage for non-diabetic patients.

Comparison Table

Other GLP-1 Options

• Liraglutide (Saxenda, Victoza): Older, daily injectable GLP-1. Less effective (~5–8% weight loss).

• Oral Semaglutide (Rybelsus): Available in pill form, but currently not approved for weight loss.

• Emerging options: Triple agonists (GLP-1/GIP/Glucagon) are in development and may surpass tirzepatide.

Safety and Considerations

• Contraindications: Personal/family history of medullary thyroid cancer, MEN 2 syndrome.

• Monitoring: Regular follow-up for GI side effects, blood sugar, and potential pancreatitis.

• Lifestyle support: Most effective when combined with diet, exercise, and behavioral interventions.

Final Thoughts

While semaglutide remains a popular first-line treatment, tirzepatide (particularly as Zepbound) is emerging as the most potent pharmacological tool for weight loss. As research evolves and competition increases, access and affordability may improve.

💡 Tip: Always consult a healthcare provider for personalized guidance on weight loss medications and their risks.

Disclaimer: This content was written with AI, along with human verification.